Four weeks
The shortest trials reporting pigmentation change; several found nothing at this point.
Protocol / Research Dosing Guide
Glutathione Research Guide: Route-by-Route Human Evidence and Safety
An evidence-organized glutathione reference that reports what human studies actually used by route, where randomized trials disagree, and where the safety record is worst.
Last reviewed September 15, 202618 minute readResearch information only
Level 4 — Randomized human trials existResults conflict by route and endpointNot FDA approved for cosmetic or intravenous use
Glutathione Quick Start
Glutathione is the body's principal intracellular antioxidant. Human trials exist across several routes, but they disagree on whether supplementation raises body stores, and the intravenous cosmetic route carries documented safety warnings. Reported effects on skin pigmentation faded after studies ended.
Why researchers care
Oxidative-stress biology, skin pigmentation, and neurologic research
Class
Endogenous tripeptide antioxidant, glutamate-cysteine-glycine
Route reported
Oral, liposomal or sublingual, intranasal, and clinician-administered intravenous
Cycle length
Study lengths ranged from four weeks to six months; no standard cycle exists
Regulatory status
Sold as a dietary supplement orally; injectable and intravenous cosmetic use is not FDA approved
Loading supplier information
Glutathione Dosing Protocol and Schedule
The supplied coverage source reports amounts by route from human studies: 250–1,000 mg daily orally, roughly 300–500 mg daily for liposomal or sublingual products, 300–600 mg daily split three times for intranasal research in Parkinson's disease, and 600–1,200 mg per clinic session for intravenous cosmetic use.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Oral capsule | 250–1,000 mg daily | Studied from four weeks to six months |
| Liposomal or sublingual | About 300–500 mg daily | Short pharmacokinetic studies of one to four weeks |
| Intranasal | 100–200 mg three times daily | Three months in Parkinson's disease trials |
| Intravenous, clinic administered | 600–1,200 mg per session | Once or twice weekly, about six weeks in cosmetic trials |
These are amounts researchers used, not recommendations. Randomized trials conflict on whether oral glutathione raises glutathione status, and intravenous cosmetic use is neither approved nor safe to self-administer.
Glutathione Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Glutathione Reconstitution Calculator
Vial-format concentration math
Concentration
400 mg/mL
Draw volume
0.1 mL
U-100 units
10
Mathematical draws
30
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Glutathione: Morning or Night?
Empty stomach?
A common label convention for oral products; it has not been established as a requirement in trials.
Split or single dose?
Oral trials used both single daily and twice-daily patterns. Intranasal research used three daily applications.
How long before anything appears?
Pigmentation changes in trials took four weeks or longer and faded after the study ended.
Missed amount?
No validated replacement procedure exists.
Glutathione Route Comparison
| Route | What human studies used | Evidence note |
|---|---|---|
| Oral capsule | 250–1,000 mg daily | Randomized trials conflict on whether body stores rise |
| Liposomal or sublingual | About 300–500 mg daily | Small studies suggest better absorption; several are industry funded |
| Intranasal | 300–600 mg daily, split three times | Tolerated in Parkinson's trials but did not beat placebo |
| Intravenous | 600–1,200 mg per clinic session | Not FDA approved cosmetically; contamination and toxicity warnings exist |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Glutathione Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Plasma half-life of infused glutathione | Very short; reported in minutes | Rapid turnover is part of why oral results conflict |
| Oral bioavailability | Disputed | Gut gamma-glutamyltransferase breaks glutathione down |
| Marketing multipliers for liposomal products | Treat as unverified | Large absorption multipliers are not confirmed by independent trials |
| Frequency rationale | Study dependent | No standard interval is established |
Glutathione Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Oral | 250 mg | Daily | Six-month randomized trial | Yes, as studied |
| Oral | 1,000 mg | Daily | Six-month randomized trial | Yes, as studied |
| Oral | 500 mg | Twice daily for four weeks | Randomized trial reporting no change | Yes, as studied |
| Intranasal | 100–200 mg | Three times daily for three months | Parkinson's disease trials | Yes, as studied |
| Intravenous | 600–1,200 mg | Once or twice weekly | Clinic cosmetic practice and one trial | No; clinician administered only |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Glutathione Reconstitution Guide
Concentration: 200 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 40 mg | 0.2 mL | 20 units |
| 80 mg | 0.4 mL | 40 units |
| 120 mg | 0.6 mL | 60 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Glutathione Works
Antioxidant role
Glutathione donates an electron from its cysteine sulfur group to neutralize reactive oxygen species.
Glutathione Human Trials and FDA Status
Current status · verified September 15, 2026
Sold as a dietary supplement orally; injectable and intravenous cosmetic use is not FDA approved
- A six-month randomized trial reported increased glutathione in blood, red cells, and other tissues at 250 mg and 1,000 mg daily.
- A four-week randomized trial at 500 mg twice daily reported no change in glutathione status or oxidative-stress markers.
- An older study of a single three-gram oral dose reported no rise in blood levels.
- Intranasal trials in Parkinson's disease reported good tolerability, but neither amount outperformed placebo.
- An intravenous skin-lightening trial reported modest short-term lightening that faded within six months.
- The FDA issued a 2019 alert after adverse reactions to a contaminated compounded glutathione injection.
Who Should Avoid Glutathione?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No adequate safety data for high-amount or injected use
Asthma
Inhaled and some sulfur-containing exposures have been associated with bronchospasm reports
Self-administered injection
Documented contamination and toxicity warnings; this route belongs with a clinician
Liver or kidney disease
Regulatory warnings cite liver, kidney, and nervous-system toxicity with injectable cosmetic use
Known sulfur or ingredient sensitivity
Reaction risk
Concurrent medicines
Interaction data are limited
Glutathione Side Effects, Risks and Safety
Oral tolerabilityGenerally well tolerated in trials
Important limitation: Trials were limited in size and length.
Gastrointestinal upsetReported
Important limitation: Common, generally mild.
Intravenous adverse reactionsDocumented
Important limitation: An FDA alert followed endotoxin-contaminated compounded product.
Severe skin reactionsReported by a foreign regulator
Important limitation: Stevens-Johnson Syndrome risk cited for injectable skin-lightening use.
Liver, kidney, or nervous-system toxicityWarned by a foreign regulator
Important limitation: Associated with injectable cosmetic use.
Long-term high-amount safetyUnknown
Important limitation: No long-term outcome trials.
Glutathione Timeline and Monitoring
Three months
Intranasal Parkinson's trials and the intravenous cosmetic trial ran on roughly this timeline.
Six months
The body-store randomized trial ran six months and reported increases at both amounts.
After stopping
Reported pigmentation effects faded; intravenous lightening faded within six months.
Glutathione Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Raising body glutathione stores | Conflicting human evidence | One six-month trial positive, others null | Route and formulation dependent |
| Skin pigmentation | Limited human evidence | Short trials with modest, temporary effects | Effects faded after stopping |
| Parkinson's disease symptoms | Not established | Intranasal trials did not beat placebo | Placebo groups also improved |
| General health or longevity outcomes | Not established | Mechanistic reasoning | No large outcome trial |
Glutathione Storage and Handling
Oral products
Follow the specific product label; liposomal liquids often require refrigeration after opening.
Unreconstituted research vial
Follow the exact product label; keep dry, cool, and away from light.
Prepared vial
Reported handling refrigerates and labels with date and concentration; no independent stability study was located.
Appearance
Glutathione solutions can look faintly tinted; particles mean the material should not be used.
Glutathione Troubleshooting
Oral results conflict with a claim you read
Trials genuinely disagree; a single positive trial does not settle the question.
Large absorption multipliers advertised
Treat figures such as several-fold or sixty-fold absorption claims as marketing-adjacent until independently confirmed.
Units do not match another chart
Recheck vial milligrams, liquid volume, entered amount, and the U-100 conversion.
Considering intravenous use
This route has the documented safety problems and belongs with a licensed clinician, never at home.
Pigmentation effect faded
Trial effects were temporary and reversed after the study ended.
Glutathione Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Glutathione | Endogenous tripeptide antioxidant | Multiple randomized trials, conflicting | Oral supplement; injectable cosmetic use not approved |
| N-acetylcysteine | Cysteine precursor | Approved medical uses plus research use | Approved for specific indications |
| Vitamin C | Dietary antioxidant | Extensive research | Supplement and approved uses |
| Alpha-lipoic acid | Redox cofactor | Mixed clinical evidence | Supplement |
Glutathione Frequently Asked Questions
What is glutathione?
A tripeptide of glutamate, cysteine, and glycine that acts as the body's main intracellular antioxidant.
Does oral glutathione work?
Randomized trials disagree. One six-month trial reported increased body stores; a four-week trial and an older single-dose study reported no change.
What amounts have human studies used orally?
Most often 250 to 1,000 mg daily, sometimes split into two doses.
Are liposomal forms better?
Small studies suggest better absorption, but sample sizes are small and several are funded by formulation makers.
What about intranasal use?
Parkinson's disease trials used 100–200 mg three times daily for three months. It was tolerable but did not outperform placebo.
Is intravenous glutathione safe?
It carries the worst safety record here. An FDA alert followed a contaminated compounded injection, and a foreign regulator warned of organ toxicity and severe skin reactions.
Is it approved for skin lightening?
No. Injectable and intravenous cosmetic use is not FDA approved.
Do skin effects last?
Reported lightening in trials was modest and faded after the studies ended.
What is the half-life?
Infused glutathione clears from plasma within minutes.
What does the calculator do?
It converts entered vial and liquid values into concentration, draw volume, and U-100 unit arithmetic only, for lyophilized research vials.
Sources and Research
Coverage source
1. Glutathione protocol coverage source
Supplied coverage source for route-by-route study amounts, handling, and information categories.
Open direct sourceHuman clinical trial
2. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Six-month randomized trial reporting increased glutathione at 250 mg and 1,000 mg daily.
Open direct sourceHuman clinical trial
3. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers
Four-week randomized trial at 500 mg twice daily reporting no change in glutathione status.
Open direct sourceHuman clinical trial
4. Phase IIb study of intranasal glutathione in Parkinson's disease
Three-month randomized trial; both amounts were tolerable but neither beat placebo.
Open direct sourceRegulatory record
5. FDA alert on compounded glutathione injection adverse reactions
Regulatory alert issued after patients reacted to an endotoxin-contaminated compounded injection.
Open direct sourceMissing information flagged for review
- Consistent evidence that oral supplementation raises body stores: Not established
- Long-term outcome trials for any route: Not established
- Established amount for injected or intravenous research use: Not established
- Standardized cosmetic efficacy evidence: Not established
- Drug-interaction data: Not established
- Safety data for sustained high-amount use: Not established